Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1995 Feb 11;310(6976):358–363. doi: 10.1136/bmj.310.6976.358

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.

N A Hamdy 1, J A Kanis 1, M N Beneton 1, C B Brown 1, J R Juttmann 1, J G Jordans 1, S Josse 1, A Meyrier 1, R L Lins 1, I T Fairey 1
PMCID: PMC2548761  PMID: 7677827

Abstract

OBJECTIVE--To determine whether alfacalcidol--used in management of overt renal bone disease--may safely prevent renal bone disease when used earlier in course of renal failure. DESIGN--Double blind, prospective, randomised, placebo controlled study. SETTING--17 nephrology centres from Belgium, France, the Netherlands, and the United Kingdom. SUBJECTS--176 patients aged 18-81 with mild to moderate chronic renal failure (creatinine clearance 15-50 ml/min) and with no clinical, biochemical, or radiographic evidence of bone disease. INTERVENTIONS--Alfacalcidol 0.25 micrograms (titrated according to serum calcium concentration) or placebo given for two years. MAIN OUTCOME MEASURES--Quantitative histology of bone to assess efficacy of treatment and renal function to assess safety. RESULTS--132 patients had histological evidence of bone disease at start of study. Biochemical, radiographic, and histological indices of bone metabolism were similar for the 89 patients given alfacalcidol and the 87 controls given placebo. After treatment, mean serum alkaline phosphatase activity and intact parathyroid hormone concentration had increased by 13% and 126% respectively in controls but had not changed in patients given alfacalcidol (P < 0.001). Hypercalcaemic episodes occurred in 10 patients given alfacalcidol (but responded to decreases in drug dose) and in three controls. Histological indices of bone turnover significantly improved in patients given alfacalcidol and significantly deteriorated in controls: among patients with abnormal bone histology before treatment, bone disease resolved in 23 (42%) of those given alfacalcidol compared with two (4%) of the controls (P < 0.001). There was no difference in rate of progression of renal failure between the two groups. CONCLUSION--Early administration of alfacalcidol can safely and beneficially alter the natural course of renal bone disease in patients with mild to moderate renal failure.

Full text

PDF
358

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler A. J., Ferran N., Berlyne G. M. Effect of inorganic phosphate on serum ionized calcium concentration in vitro: a reassessment of the "trade-off hypothesis". Kidney Int. 1985 Dec;28(6):932–935. doi: 10.1038/ki.1985.220. [DOI] [PubMed] [Google Scholar]
  2. Alvarez-Ude F., Feest T. G., Ward M. K., Pierides A. M., Ellis H. A., Peart M., Simpson W., Weightman D., Kerr D. N. Hemodialysis bone disease: correlation between clinical, histologic, and other findings. Kidney Int. 1978 Jul;14(1):68–73. doi: 10.1038/ki.1978.90. [DOI] [PubMed] [Google Scholar]
  3. Bricker N. S. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med. 1972 May 18;286(20):1093–1099. doi: 10.1056/NEJM197205182862009. [DOI] [PubMed] [Google Scholar]
  4. Brickman A. S., Coburn J. W., Massry S. G., Norman A. W. 1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure. Ann Intern Med. 1974 Feb;80(2):161–168. doi: 10.7326/0003-4819-80-2-161. [DOI] [PubMed] [Google Scholar]
  5. Brown R. C., Aston J. P., Weeks I., Woodhead J. S. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab. 1987 Sep;65(3):407–414. doi: 10.1210/jcem-65-3-407. [DOI] [PubMed] [Google Scholar]
  6. Cantley L. K., Russell J., Lettieri D., Sherwood L. M. 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology. 1985 Nov;117(5):2114–2119. doi: 10.1210/endo-117-5-2114. [DOI] [PubMed] [Google Scholar]
  7. Chapuy M. C., Arlot M. E., Duboeuf F., Brun J., Crouzet B., Arnaud S., Delmas P. D., Meunier P. J. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992 Dec 3;327(23):1637–1642. doi: 10.1056/NEJM199212033272305. [DOI] [PubMed] [Google Scholar]
  8. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  9. Cundy T. F., Hamdy N. A., Kanis J. A. Factors modifying the secretion and action of parathyroid hormone in renal failure. Contrib Nephrol. 1988;64:5–15. doi: 10.1159/000415721. [DOI] [PubMed] [Google Scholar]
  10. Cundy T., Hand D. J., Oliver D. O., Woods C. G., Wright F. W., Kanis J. A. Who gets renal bone disease before beginning dialysis? Br Med J (Clin Res Ed) 1985 Jan 26;290(6464):271–275. doi: 10.1136/bmj.290.6464.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DeLuca H. F. The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone. N Engl J Med. 1973 Aug 16;289(7):359–365. doi: 10.1056/NEJM197308162890710. [DOI] [PubMed] [Google Scholar]
  12. Ellis H. A., Peart K. M. Azotaemic renal osteodystrophy: a quantitative study on iliac bone. J Clin Pathol. 1973 Feb;26(2):83–101. doi: 10.1136/jcp.26.2.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goodman W. G., Coburn J. W. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med. 1992;43:227–237. doi: 10.1146/annurev.me.43.020192.001303. [DOI] [PubMed] [Google Scholar]
  14. Kanis J. A., Cundy T. F., Hamdy N. A. Renal osteodystrophy. Baillieres Clin Endocrinol Metab. 1988 Feb;2(1):193–241. doi: 10.1016/s0950-351x(88)80013-2. [DOI] [PubMed] [Google Scholar]
  15. Kanis J. A., Cundy T., Earnshaw M., Henderson R. G., Heynen G., Naik R., Russell R. G., Smith R., Woods C. G. Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses. Q J Med. 1979 Apr;48(190):289–322. [PubMed] [Google Scholar]
  16. Kanis J. A., Earnshaw M., Heynen G., Ledingham J. G., Oliver D. O., Russell G. G., Woods C. G., Franchimont P., Gaspar S. Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin. N Engl J Med. 1977 May 12;296(19):1073–1079. doi: 10.1056/NEJM197705122961901. [DOI] [PubMed] [Google Scholar]
  17. Lehner T., Adams C. W. Lipid histochemistry of Fabry's disease. J Pathol Bacteriol. 1968 Apr;95(2):411–415. doi: 10.1002/path.1700950209. [DOI] [PubMed] [Google Scholar]
  18. Llach F., Massry S. G. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab. 1985 Oct;61(4):601–606. doi: 10.1210/jcem-61-4-601. [DOI] [PubMed] [Google Scholar]
  19. Lopez-Hilker S., Galceran T., Chan Y. L., Rapp N., Martin K. J., Slatopolsky E. Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest. 1986 Oct;78(4):1097–1102. doi: 10.1172/JCI112666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Malluche H. H., Ritz E., Lange H. P., Kutschera L., Hodgson M., Seiffert U., Schoeppe W. Bone histology in incipient and advanced renal failure. Kidney Int. 1976 Apr;9(4):355–362. doi: 10.1038/ki.1976.42. [DOI] [PubMed] [Google Scholar]
  21. Malluche H., Faugere M. C. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int. 1990 Aug;38(2):193–211. doi: 10.1038/ki.1990.187. [DOI] [PubMed] [Google Scholar]
  22. Maloney N. A., Ott S. M., Alfrey A. C., Miller N. L., Coburn J. W., Sherrard D. J. Histological quantitation of aluminum in iliac bone from patients with renal failure. J Lab Clin Med. 1982 Feb;99(2):206–216. [PubMed] [Google Scholar]
  23. Massry S. G., Stein R., Garty J., Arieff A. I., Coburn J. W., Norman A. W., Friedler R. M. Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25 (OH)2 D3. Kidney Int. 1976 Jun;9(6):467–474. doi: 10.1038/ki.1976.60. [DOI] [PubMed] [Google Scholar]
  24. Mawer E. B., Taylor C. M., Backhouse J., Lumb G. A., Stanbury S. W. Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet. 1973 Mar 24;1(7804):626–628. doi: 10.1016/s0140-6736(73)92197-1. [DOI] [PubMed] [Google Scholar]
  25. Parfitt A. M., Drezner M. K., Glorieux F. H., Kanis J. A., Malluche H., Meunier P. J., Ott S. M., Recker R. R. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987 Dec;2(6):595–610. doi: 10.1002/jbmr.5650020617. [DOI] [PubMed] [Google Scholar]
  26. Portale A. A., Booth B. E., Halloran B. P., Morris R. C., Jr Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984 Jun;73(6):1580–1589. doi: 10.1172/JCI111365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Silver J., Russell J., Sherwood L. M. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4270–4273. doi: 10.1073/pnas.82.12.4270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Somerville P. J., Kaye M. Resistance to parathyroid hormone in renal failure: role of vitamin D metabolites. Kidney Int. 1978 Sep;14(3):245–254. doi: 10.1038/ki.1978.116. [DOI] [PubMed] [Google Scholar]
  29. Szabo A., Merke J., Beier E., Mall G., Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. 1989 Apr;35(4):1049–1056. doi: 10.1038/ki.1989.89. [DOI] [PubMed] [Google Scholar]
  30. Taube T., Beneton M. N., McCloskey E. V., Rogers S., Greaves M., Kanis J. A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992 Oct;49(4):192–198. doi: 10.1111/j.1600-0609.1992.tb00046.x. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES